Insmed Dominates the Respiratory Market – Revenue Expected to More Than Double by 2026!
Reading Time: 2 minutes
Insmed (INSM) has specialized as a biopharmaceutical company in the development and marketing of therapies for severe, rare, and currently inadequately treated respiratory and inflammatory diseases. With ARIKAYCE and BRINSUPRI, revenues are expected to more than double by 2026. Morgan Stanley analysts raised the price target from $166 to $212 on March 30 and upgraded the rating from "Equal Weight" to "Overweight." Sales of BRINSUPRI alone are projected to reach $1.2 billion in 2026. With the positive results from the Phase 3b ENCORE study published...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
